RANK–RANKL–OPG pathway (RANK/RANKL/OPG pathway)

The RANK–RANKL–OPG pathway is a crucial signaling network regulating bone metabolism, immune response, and cell survival. RANKL, a tumor necrosis factor (TNF) family cytokine, is expressed by osteoblasts and activated T cells; it binds to RANK, a receptor on osteoclast precursors and dendritic cells, promoting osteoclast maturation, survival, and bone resorption. OPG, a soluble decoy receptor predominantly produced by osteoblasts, inhibits this process by binding to RANKL and preventing it from activating RANK. Dysregulation of this pathway contributes to diseases characterized by excessive bone resorption (like osteoporosis and bone metastases) and is a target for agents (such as denosumab) that aim to restore bone balance or manage cancer-related bone disease.

Other names

RANK-RANKL-OPG signaling pathwayRANK/RANKL/OPG systemRANKL signaling pathwayTNFSF11–RANK–OPG pathwayOsteoprotegerin/RANK/RANKL pathway

Inhibition of RANKL binding to RANK (by monoclonal antibody, e.g., denosumab or OPG analogs), preventing osteoclast activation and bone resorption. Mimicking OPG function (decoy receptor, blocks RANKL). Indirect modulation of pathway activity.